WO2003059389A1 - Compositions medicamenteuses presentant une meilleure absorption orale - Google Patents
Compositions medicamenteuses presentant une meilleure absorption orale Download PDFInfo
- Publication number
- WO2003059389A1 WO2003059389A1 PCT/JP2003/000269 JP0300269W WO03059389A1 WO 2003059389 A1 WO2003059389 A1 WO 2003059389A1 JP 0300269 W JP0300269 W JP 0300269W WO 03059389 A1 WO03059389 A1 WO 03059389A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methacrylate copolymer
- aminoalkyl methacrylate
- acidic substance
- pharmaceutical composition
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
Definitions
- composition for improving oral absorption is provided.
- the present invention relates to an inhibitor for the degradation of a physiologically active peptide by a digestive enzyme, comprising an aminoalkyl methacrylate copolymer E as an active ingredient.
- the present invention also relates to a viscosity reducing agent for a mucus layer distributed on a digestive tract mucosa, comprising aminoalkyl methacrylate copolymer E as an active ingredient.
- the present invention provides that, by administering aminoalkyl methacrylate copolymer E, (1) the physiologically active peptide is degraded by digestive enzymes in the gastrointestinal mucosa and the mucus layer distributed on the mucous membrane or the mucosa.
- the present invention relates to a method for improving the permeability, and (4) a method for improving the permeability of a bioactive peptide in the gastrointestinal mucosa.
- a pharmaceutical composition for improving oral absorption comprising a physiologically active peptide and an aminoalkyl methacrylate copolymer E, in particular, a physiologically active peptide, an aminoalkyl methacrylate copolymer E, and an acidic substance.
- the present invention relates to a pharmaceutical composition for improving oral absorption, wherein the three components are close to each other, and at least the polymer and the acidic substance are uniformly mixed.
- Orally administered drugs quickly pass through the esophagus and reach the stomach.
- the stomach wall is composed of three layers: mucous membrane, muscular layer, and serosa, but unlike the small intestine, the effective area of absorption is small, so it is considered that its role as an absorption site is small except for some drugs.
- the human small intestine consisting of the duodenum, jejunum and ileum, is the longest in the gastrointestinal tract and has a large surface area available for absorption, making it a suitable site for absorption for many drugs.
- the absorption is large in the case of highly water-soluble or high-molecular-weight drugs. Limited.
- the mucus layer that constantly covers the gastrointestinal mucosa is also a barrier that inhibits gastrointestinal absorption of bioactive peptides such as pasopressin. Therefore, the orally administered drug is absorbed in the living body only after passing through two mulia layers covering the mucosal surface of the digestive tract and the mucous membrane.
- bile salts having surface-active action WO9606635
- sucrose fatty acid esters sucrose fatty acid esters
- 0-acyl-L-carnitines having 8 to 18 carbon atoms
- SLS sodium lauryl sulfate
- SLS bile salts in combination with SLS
- Chelating agents such as EDTA (J. Pharm. Pharmacol., 51, No. 11, 1241-50, 1999), and EGTA, or trypsin inhibitor (J. Pharm. Pharmacol., 50, No. 8, 913-20) , 1998) and the like.
- calcium ions are extracted to loosen the intercellular spaces and promote the permeability of the polymer substance.However, at physiological pH (near neutral), the absorption effect is required unless the concentration is relatively high. It has not been reported, and mucosal damage due to the extraction of calcium ions has been reported.
- Examples include a method using a polyacrylic acid gel base such as polycarbophil, carbophil, or (meth) acrylic acid-maleic acid copolymer (US Pat. No. 6,004,575), and a polymer substance such as chitosan.
- the method is said to promote absorption of a bioactive peptide by loosening the cell gap.
- polyacrylic acid gel base can suppress the degradation of bioactive peptides by digestive enzymes by forming chelate with metal ion (Int.J. Pharm., 141, pp. 39-52, 1996).
- it is said that practical use of the base is difficult because the base shows a high viscosity even when the polymer itself has a relatively low concentration.
- a (meth) acrylic acid-maleic acid copolymer described in US Pat. No. 6,004,575 may be mentioned as one having reduced viscosity of the polyacrylic acid gel base, but the polymer has a large number of carboxyl groups in structure. Therefore, it is considered that the use of the polymer increases the viscosity of the mucus layer distributed in the gastrointestinal mucosa.
- Chitosan has been reported to promote absorption by loosening the intercellular space (Int. J. Pharm, 185, 1, pp. 73-82, 1999). However, chitosan has no inhibitory effect on bioactive peptide degrading enzymes (Int. J. Pharm, 159, pp.243-253, 1997) and interacts with the mucus layer distributed on the gastrointestinal mucosa to reduce the permeability of substances in the mucus layer (Eur. J. Pharm. Sci., 8, No. 4). 335-43, 1999), it is unlikely that sufficient oral absorption would be obtained even when chitosan was used.
- the following method is further known as a technique using the aminoalkyl methacrylate copolymer E to improve the oral absorption of a drug.
- International Publication Pamphlet WO00 / 43041A1 discloses a pharmaceutical composition for improving oral absorption comprising a drug which forms a poorly absorbable complex with bile acid and is hardly absorbed, and an aminoalkyl methacrylate copolymer: E
- the invention relating to the invention is specifically described.
- the pamphlet also discloses an invention relating to a pharmaceutical composition obtained by dissolving or suspending an aminoalkyl methacrylate copolymer E and a surfactant in a solvent and spray-drying the solution.
- the aminoalkyl methatalylate copolymer E which is an active ingredient of the present invention, inhibits (1) inhibition of digestion of bioactive peptides by digestive enzymes in the gastrointestinal mucosa and / or mucus layer distributed on the mucous membrane. Inhibitory action), (1) action to reduce the viscosity of the gastrointestinal mucosa and / or the mucus layer distributed on the mucous membrane (action to improve the permeability of bioactive peptides in the mucus layer), (3) action in the gastrointestinal mucosa There is no disclosure or suggestion of having three functions, such as an action to improve the permeability of the bioactive peptide.
- International Publication Pamphlet WO00 / 02574A1 discloses an invention related to a powdery transmucosal administration preparation containing a polymer drug and an aminoalkyl methacrylate copolymer E as a cationic polymer. I have. However, in the examples, only the preparation for nasal administration was produced, and only the effect on nasal mucosal absorption was confirmed. Aminoalkyl methyl acrylate copolymer E could not be used as a bioactive substance from other transmucosal. Peptide absorption, especially when formulated into oral dosage form No effect has been disclosed on the absorption of the physiologically active peptide.
- aminoalkyl methacrylate copolymer E is a copolymer of methyl methacrylate and butyl methacrylate and dimethylaminoethyl methacrylate, which was developed by Rohm Co., Ltd. and is Eudragit TM E100 or Eudragit TM EPO. (All of which are marketed under the brand name of Riihm GmbH) and have an average molecular weight of 150,000 (Pharmaceutical Excipient Standard, F76-77, 1998, Pharmaceutical Affairs Date Chichido; Handbook of Pharmaceutical Ecipients (second edition p362-366, 1994, American Pharmaceutical Association, Washington and The Pharmaceutical Press, London) 0
- Aminoalkyl methacrylate copolymer E has properties such as (1) it dissolves quickly in gastric juice, (2) dissolves in a buffer solution of pH 5.0 or less, and swells in a buffer solution of pH 5.0 or more. It is a prominent film coating base widely used for masking the bitterness and color of tablets and granules, and for preventing moisture. Conventionally, aminoalkyl methacrylate copolymer E has been used for masking the bitterness and color of a drug, for preventing moisture, and for solubilizing a drug.
- the present inventors have conducted intensive studies with the aim of developing oral formulations of bioactive peptides such as insulin and calcitonin, and found that bioactive peptides were degraded by enzymes in the digestive tract.
- bioactive peptides such as insulin and calcitonin
- the permeability of bioactive peptides decreased diffusion
- the inventors of the present application have conventionally determined that the permeability of a drug in Investigations were conducted using force-popol, a substance known to improve, and found that carbopol interacts with components in the mucus layer to increase the viscosity of the mucus layer.
- the diffusion rate of the bioactive peptide decreases, which means that the time required for the bioactive peptide to pass through the mucus layer and reach the mucous membrane is extended.
- Increased viscosity means that the bioactive peptide will be in contact with the digestive enzymes in the digestive tract for longer. Therefore, the present inventors believe that the increase in viscosity in the mucosal layer decreases the permeability of the bioactive peptide in the mucus layer and Z or the mucous membrane, so that the bioactive peptide is easily decomposed by digestive enzymes, As a result, it is thought that the absorbability in the living body is reduced.
- the present applicant relates to a drug which forms a poorly absorbable complex with bile acid and reduces oral absorption, in which aminoalkyl methacrylate copolymer E inhibits the complex formation and dissociates Z or the complex. And obtained a patent application (International Publication Pamphlet WO00 / 43041Al).
- Applicant has continued to study and has found that an oral absorption improver for improving drug permeability in a gastrointestinal mucosa and / or a mucus layer distributed on the mucous membrane containing an aminoalkyl methyl acrylate copolymer E as an active ingredient, Aminoalkyl methacrylate copolymer in the coexistence of acidic substance-obtained a finding that a pharmaceutical composition containing E can improve drug permeability in the mucous layer distributed on the gastrointestinal mucosa and / or mucosa.
- a patent application was filed (PCT / JP01 / 06135, USSN09 / 907, 557 (filed on July 16, 2001)).
- aminoalkyl methacrylate copolymer E (1) a mucous layer distributed on the gastrointestinal mucosa and / or the mucosa and / or Inhibits (suppresses) the degradation of bioactive peptides by enzymes that degrade bioactive peptides at sites in the lumen; (1) Reduces the viscosity of gastrointestinal mucosa and the mucus layer distributed on Z or its mucous membrane (in mucus layer Improves the permeability of bioactive peptides (3) New knowledge has been obtained that it simultaneously has the effect of improving the permeability of bioactive peptides in the gastrointestinal mucosa.
- aminoalkyl methacrylate copolymer E in a solution state is delivered to the mucus layer and Z or mucous membrane prior to drug permeation, thereby preventing the components contained therein from interacting with the drug, or It is thought that this is caused by improving the permeability by increasing the permeability by acting on the component (1) to lower the viscosity, thereby improving the drug permeability in epithelial cells and / or intercellular spaces.
- the present inventors have sought to provide, for the first time, an oral preparation of a bioactive peptide, which was considered to lose its activity by enzymes in the gastrointestinal tract, if aminoaminoalkyl methacrylate copolymer E having the above three actions simultaneously was used.
- the aminoalkyl methacrylate copolymer E, the physiologically active peptide and the acidic substance were regarded as essential ingredients, and the ingredients were brought close to each other, and more preferably Uniformly mixes these three components, at least an aminoalkyl methacrylate copolymer E, and an acidic substance, and delivers these substances in solution in the gastrointestinal tract lumen or in the mucous layer of the gastrointestinal tract and Z or mucosa. And significantly improved the oral absorption of bioactive peptides.
- the present invention has been completed based on these findings.
- Aminoalkyl methacrylate copolymer E as an active ingredient, a viscosity reducing agent for mucus layer distributed on gastrointestinal mucosa,
- a method for suppressing the degradation of a bioactive peptide by administering an aminoalkyl methacrylate copolymer E to inhibit the degradation of a bioactive peptide by digestive enzymes,
- a pharmaceutical composition for improving oral absorption comprising a physiologically active peptide and aminoalkyl methacrylate copolymer E,
- compositions comprising a physiologically active peptide, aminoalkyl methacrylate copolymer E, and an acidic substance, wherein the three components are close to each other, and at least the polymer and the acidic substance are uniformly mixed.
- composition according to the above 21 or 22, wherein the form as a preparation is one or more selected from the group consisting of granules, tablets, capsules, and liquids
- composition according to the above 30, wherein the physiologically active peptide is calcitonin, insulin, or vasopressin.
- gastrointestinal tract means the small intestine consisting of the duodenum, jejunum, and ileum, the colon consisting of the ascending colon, the transverse colon, the descending colon, and the sigmoid colon, and the large intestine consisting of the colon and rectum. .
- in the lumen of the gastrointestinal tract means the inside of the lumen through which the food and the like pass, for example, on the surface of the mucus layer distributed on the mucosal surface of the “gastrointestinal tract”.
- the present invention provides an aminoalkyl methacrylate copolymer E as an active ingredient, which comprises (A-11) a mucus layer and Z or a mucus layer distributed anywhere in the digestive tract, for example, on the mucosa of the digestive tract and on Z or its mucosa.
- Use to inhibit (inhibit) the degradation of bioactive peptides by digestive enzymes present in the digestive tract lumen above, (A-2) gastrointestinal mucosa and / or (A-3) reduces the viscosity of the mucus layer present in the mucous layer distributed on the mucous membrane.
- A-3) Based on the action of (A-2), increases the permeability (diffusion) of the bioactive peptide in the mucus layer.
- the aminoalkyl methacrylate copolymer E is used alone or, preferably, in the presence of an acidic substance.
- the amount of the polymer used is an amount that suppresses the decomposition of the bioactive peptide, an amount that reduces the viscosity of the mucus layer distributed on the gastrointestinal mucosa, or a gastric layer that is distributed on the gastrointestinal mucosa and Z or mucous membrane.
- the amount is not particularly limited as long as it improves the permeability of the bioactive peptide.
- the amount (by weight) is usually 10 mg to 3000 mg, preferably 25 mg to 2500 mg, and more preferably 50 mg to 2000 mg.
- the present invention provides (B-1) a mucous layer and / or a mucus layer distributed on any part of the digestive tract, for example, the digestive tract mucosa and Z or the mucosa by administering the aminoalkyl methacrylate copolymer E.
- (B_3) A method to increase the permeability (diffusion) of bioactive peptides in the mucus layer based on the action of (B-2), (B-4) Bioactivity in the gastrointestinal mucosa Provided is a method for improving the permeability of a peptide.
- the aminoalkyl methacrylate copolymer E is used alone or, preferably, in the presence of an acidic substance.
- the amount of the polymer used is physiological An amount that inhibits the decomposition of active peptides, an amount that reduces the viscosity of the mucus layer distributed on the gastrointestinal mucosa, or the permeability of bioactive peptides in the mucous layer distributed on the gastrointestinal mucosa and Z or mucosa. There is no particular limitation as long as the amount improves.
- the amount (by weight) is usually 10 mg to 3000 mg, preferably 25 mg to 2500 mg, and more preferably 50 mg to 2000 mg.
- proximity refers to an aminoalkyl within the scope of the present invention, that is, an aminoalkyl to the extent that it can improve the permeability of the bioactive peptide in the mucous layer of the gastrointestinal tract and Z or mucous membrane and improve oral absorption.
- Methacrylate copolymer E and acidic substances are homogeneously mixed, and means that each component exists close to each other in a solid state or a liquid state. I do.
- the form in which the bioactive peptide is processed for example, saccharide, starch, hydroxypropyl methylcellulose
- Etc. are also included in the scope of the present invention.
- “uniformly” means, for example, as shown in FIG. 1 (l-2a), a bioactive peptide, an aminoalkyl methacrylate copolymer E, and an acidic substance (a bioactive peptide is a preferred embodiment). Even if they are scattered, each component as a whole means a uniform state as shown in Figure l (l-2b). Conversely, bioactivity, aminoalkyl methacrylate copolymer E, and acidic A state in which each component is unevenly distributed, such as a three-layer tablet, is not “uniform”.
- homogeneously blended refers to a state of being blended by a method known per se in the pharmaceutical field, for example, physical mixing, spray drying, freeze drying, granulation (wet granulation, dry granulation). Or a liquid composition in which each component is suspended and Z or dissolved in a pharmaceutically acceptable solvent such as water.
- FIG. 1 shows some of the embodiments, but does not limit these embodiments.
- the pharmaceutical composition for improving oral absorption comprising the decomposition inhibitor or the viscosity reducing agent of the present invention, or the decomposition inhibitor or the viscosity reducing agent may be composed of only the aminoalkyl methyl acrylate copolymer E. It can also be in the form of a preparation containing the polymer together with a pharmaceutically acceptable carrier.
- the degradation inhibitor or viscosity reducing agent of the present invention comprises the above-mentioned polymer as an essential component
- the pharmaceutical composition for improving oral absorption containing the degradation inhibitor or viscosity reducing agent comprises a physiologically active peptide and an aminoalkylmethacrylate.
- the carrier include excipients such as a filler, a diluent such as a filler, a disintegrant, and a lubricant, or a stabilizer such as a stabilizer, which are generally used depending on the use form of the preparation. Is appropriately selected and used depending on the dosage unit form of the pharmaceutical preparation.
- various forms can be selected according to the purpose of treatment, and typical examples are tablets, pills, powders, solutions, suspensions, emulsions, condyles, capsules Injections (solutions, suspensions, etc.).
- the invention relating to the pharmaceutical composition for improving oral absorption of the present invention is described below.
- the present invention relates to a bioactive peptide and an aminoalkyl methacrylate copolymer.
- a pharmaceutical composition for improving oral absorption containing E preferably an aminoalkyl methacrylate copolymer E, and an acidic substance, particularly in a neutral to weakly alkaline site of the digestive tract.
- a pharmaceutical composition for improving oral absorption which comprises uniformly dissolving a polymer with an amount of an acidic substance that neutralizes 10% or more of the basic groups of the polymer.
- the pharmaceutical composition for improving oral absorption which comprises a physiologically active peptide and an aminoaminomethacrylate copolymer E of the present invention (preferably, further containing an acidic substance uniformly), (C-1) Since the polymer can be dissolved even in the neutral or weakly alkaline region of the gastrointestinal tract, bioactive peptides decomposed in the gastrointestinal tract, degraded by enzymes in the gastrointestinal tract, and on the gastrointestinal mucosa Oral absorption can be improved for bioactive peptides whose permeability is reduced in the mucus layer distributed in (C-12).
- the optimal absorption site differs depending on the type of bioactive peptide, so optimal absorption
- it is necessary to design the formulation in consideration of the site it is necessary not only in the small intestine with a large effective absorption area such as the duodenum, jejunum and ileum in the upper small intestine, but also in the digestive tract with little water
- Aminoalkyl methacrylate copolymer E can dissolve in the colon (including the ascending, transverse, descending, and sigmoid colons) or the large intestine such as the rectum.
- Aminoalkyl methacrylate copolymer E can be used as an effective absorption site for active peptides.
- C-4) The activity of inhibiting the degradation of bioactive peptides by degrading enzymes and the action of Z or delaying bioactive peptides can be suppressed. It has the effect of improving the oral absorption of the peptide.
- bioactive peptides used in the present invention are provided for treating or preventing diseases.
- physiologically active peptides include insulin, calcitonin, angiotensin, vasopressin, desmopressin, LH-RH (luteinizing hormone-releasing hormone), somatosustin, glucagon, human xylosine, gastrin, cyclosporine, somatomedin, Secretin, h- ⁇ (human atrial natriuretic peptide), ACTH (adrenocorticotropic hormone), MSH (melanophore stimulating hormone), / 3-endorphin, muramyl dipeptide, enkephalin, neurotensin, bombesi , VIP (vasoactive intestinal peptide), CCK-8 (cholecystokinin-18), PTH (parathyroid hormone), CGRP (calcitonin gene-related peptide), TRH (
- the peptides and proteins include not only those of natural origin but also pharmacologically active derivatives and analogs thereof.
- the calcitonin targeted in the present invention includes not only naturally occurring products such as salmon calcitonin, human calcitonin, porcine calcitonin, eel calcitonin, and chicken calcitonin, but also recombinants thereof.
- Insulin includes not only human insulin, bush insulin, and insulin but also genetically modified forms thereof.
- the amount of the bioactive peptide is not particularly limited as long as it is an effective amount for treating or preventing a disease.
- the state when the aminoalkyl methacrylate copolymer E is blended in the pharmaceutical composition is not particularly limited as long as it is close to the physiologically active peptide and is uniformly blended with the acidic substance described below. Not done.
- the state includes, for example, a solid such as a powder of the polymer itself, or a suspension of the polymer in water and Z or the like. Or a liquid such as a dissolved aqueous solution.
- the powdering method include a method known per se, for example, a pulverization method, a spray drying method, a freeze drying method, a wet granulation method, and a dry granulation method.
- the aminoalkyl methacrylate copolymer E may have a free amino group or may be a soluble salt. In the case of a soluble salt, it is preferably prepared by dissolving or dissolving and suspending the aminoalkyl methacrylate copolymer E together with an acid, followed by spray drying or freeze drying.
- the aminoalkyl methacrylate copolymer E may contain a surfactant.
- the surfactant to be added is usually pharmaceutically acceptable and is not particularly limited as long as it reduces the water repellency of the polymer.
- Such surfactants include, for example, nonionic surfactants (for example, polyoxyethylene surfactants (for example, polysorbate 80, polyoxyl stearate 40, lauromacrogol, polyoxyethylene hydrogenated castor oil ( HCO-60), sucrose fatty acid esters, etc.), ionic surfactants (anionic surfactants (eg, sodium lauryl sulfate), etc.), cationic surfactants (eg, benzalkonium chloride, etc.), amphoteric surfactants ( These may be used alone or in combination of two or more. The amount of such a surfactant may be an amount that reduces the water repellency of the polymer.
- nonionic surfactants for example, polyoxyethylene surfactants (for example, polysorbate 80, polyoxyl stearate 40, lauromacrogol, polyoxyethylene hydrogenated castor oil ( HCO-60), sucrose fatty acid esters, etc.
- ionic surfactants anionic surfactants (eg, sodium
- the amount is not particularly limited, but is usually about 0.01 to 10 parts by weight, preferably about 0.01 to 5 parts by weight, more preferably about 0.01 to 5 parts by weight, per 1 part by weight of the polymer.
- the solvent for dissolving or suspending the aminoalkyl methacrylate copolymer E is preferably a pharmaceutically acceptable solvent. Examples include, but are not limited to, water, organic solvents (eg, methanol, ethanol, isopropanol, acetone, etc.), and mixtures of water and organic solvents, etc.
- the pharmaceutical composition of the present invention includes It may also contain various excipients used and other additives. Examples of the excipient or additive include bulking agents such as lactose and starch.
- the amount of the aminoalkyl methacrylate copolymer E is not particularly limited as long as it is appropriately adjusted in relation to the amount of the physiologically active peptide, but is usually 0.01 part by weight or more based on 1 part by weight of the physiologically active peptide. And preferably 0.1 to 1,000,000 parts by weight, more preferably 0.5 to: L00000 parts by weight, and still more preferably:! To 100000 parts by weight.
- the amount (by weight) is usually 10 mg to 3000 mg, preferably 25 mg to 2500 mg, more preferably 50 mg to 2000 mg.
- the aminoalkyl methacrylate copolymer E may further contain a surfactant for the purpose of further promoting absorption.
- Such surfactants include nonionic surfactants (eg, polyoxyethylene surfactants (eg, polysorbate 80, polyoxyl stearate 40, lauromacrogol, polyoxyethylene hydrogenated castor oil (HCO-60)). ), Sucrose fatty acid esters, etc.), ionic surfactants (anionic surfactants (eg, sodium lauryl sulfate, etc.)), ionic surfactants (eg, benzalkonidum chloride, etc.), amphoteric surfactants (lecithin, etc.) These may be used alone or in combination of two or more.
- nonionic surfactants eg, polyoxyethylene surfactants (eg, polysorbate 80, polyoxyl stearate 40, lauromacrogol, polyoxyethylene hydrogenated castor oil (HCO-60)
- HCO-60 polyoxyethylene hydrogenated castor oil
- ionic surfactants anionic surfactants (eg, sodium lauryl sulfate, etc.
- the acidic substance used in the present invention is pharmaceutically acceptable and neutralizes a part or all of the basic groups of the aminoalkyl methacrylate copolymer E in the presence of water to dissolve the polymer.
- the acidic substance is an inorganic acid and / or an organic acid whose pH is 6 or less when the substance lg is dissolved or suspended in 50 ml of water. Is an acid.
- the acidic substance used in the present invention include inorganic acids such as hydrochloric acid, phosphoric acid, potassium dihydrogen phosphate and sodium dihydrogen phosphate; citric acid, lactic acid, tartaric acid, and fumaric acid.
- Acids fluoric acid, acetic acid, oxalic acid, malonic acid, adipic acid, phytic acid, succinic acid, daltaric acid, maleic acid, malic acid, mandelic acid, ascorbic acid, benzoic acid, methanesulfonic acid, acetic acid Organic acids such as, cabronic acid, caprylic acid, lauric acid, arachinic acid, eric acid, linoleic acid, linolenic acid, oleic acid, palmitic acid, myristic acid, and stearic acid; aspartic acid, glutamic acid (preferably L-form ), Cysteine (preferably L-form), arginine hydrochloride, lysine hydrochloride, and glumic acid (preferably L-form) hydrochloride. These can be used alone or in combination of two or more.
- the amount of the acidic substance to be added is not particularly limited as long as the polymer can be dissolved by neutralizing a part or all of the basic groups of the aminoalkyl methacrylate copolymer E in the presence of moisture. Not done.
- the amount of the substance to be added is usually an amount that neutralizes about 10% or more of the basic groups of the polymer, preferably about 15% or more, and more preferably about 30% or more. Neutralizing amount, more preferably about 40% or more, and optimally 50% or more. Spray-dried products are preferred when 50% or more of the acidic substance coexists, since they do not show aggregation when stored for a long period of time and are easy to handle in production.
- the amount of the acidic substance is appropriately adjusted in consideration of the solubility and Z or acidity of the substance, but is usually 0.005 to 50 parts by weight based on 1 part by weight of the aminoalkyl methacrylate copolymer E. It is preferably 0.01 to 30 parts by weight, more preferably 0.03 to 10 parts by weight.
- the acidic substance used in the present invention is spray-dried by adding lmol / 1 hydrochloric acid 312.5 g to 500 g of Eudragit E, for example, it can be calculated by the following formula (I).
- the aminoalkyl methacrylate copolymer E used in the present invention is uniformly mixed with the acidic substance in a state in which the aminoalkyl methacrylate copolymer E is closely and uniformly mixed with the physiologically active peptide in the presence of moisture.
- the state is preferably a state in which the physiologically active peptide, the polymer, and the acid substance are uniformly mixed. Examples of such a state include an embodiment in which the composition is blended by a method known per se.
- aminoalkyl methacrylate copolymer E prepared by the method already described for the formulation of the aminoalkyl methacrylate copolymer E, or the aminoalkyl methacrylate copolymer E and an acidic substance, or aminoalkyl methacrylate.
- Dissolve acrylate copolymer E and acidic substances in a pharmaceutically acceptable solvent eg, water, alcohol (methyl-, ethyl-, propyl-, butyl-, etc.) or a mixture thereof
- a pharmaceutically acceptable solvent eg, water, alcohol (methyl-, ethyl-, propyl-, butyl-, etc.
- the suspended liquid is made into a powder by a method known per se, for example, spray drying, etc.
- the aminoalkyl methacrylate copolymer E and an acidic substance are mixed or granulated by a method known per se.
- an aminoalkyl meta Examples include a solution in which the copolymer C and the acidic substance are dissolved and Z or suspended in a pharmaceutically acceptable solvent, an embodiment in which a physiologically active peptide is further added to the above-described embodiment, and the like.
- Pharmaceutical composition in which these embodiments can be specifically taken Is not particularly limited as long as it is a dosage form as a preparation that can be administered orally.
- preparations include powders, tablets, capsules, liquids, suspensions, emulsions, and capsules filled with liquids, suspensions, emulsions, and the like.
- the preparation can be produced by a method known per se.
- Specific examples of such preparations include those prepared preferably such that the aminoalkyl methacrylate copolymer E and the acidic substance used in the present invention are present in the vicinity of a physiologically active peptide.
- Capsules include, for example, a solution / suspension prepared by dissolving and / or suspending an aminoalkyl methacrylate copolymer E and an acidic substance in a pharmaceutically acceptable solvent; For example, gelatin capsules and the like filled with are mentioned.
- the mixture examples include a mixture in which aminoalkyl methacrylate copolymer E and an acidic substance are mixed by a method known per se, and the mixture is mixed with a bioactive peptide.
- a pharmaceutically acceptable solvent such as water is added, or if desired, for example, hydroxypropylpyrmethylcellulose or the like is added.
- Granules obtained by adding a binder are used.
- the tablet or capsule include a tablet obtained by mixing a pharmaceutical excipient with the mixture or the granulated product and tableting, and a capsule prepared by filling the granulated product into a gelatin capsule, for example.
- an enteric preparation for example, the above-mentioned granulated product is treated with an enteric substance (for example, a 1: 1 copolymer of methyl methacrylate and methacrylic acid (trade name: Eudragit TML, Rohm GmbH), methyl methacrylate) 2: 1 copolymer of methacrylic acid (trade name: Eudragit TM S , Rohm GmbH), 1: 1 copolymer of ethyl acrylate and methacrylic acid (trade name: Eudragit TM LD-55, Rohm GmbH 3 ⁇ 4 :), hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate Enteric-coated preparations coated with silicate, carboxymethylethylcellulose, cellulose acetate phthalate, shellac, zein, etc.) or tablets obtained by tableting the granules described above are enteric-coated (same as above) And enteric-coated preparations coated with.
- an enteric substance for
- the pharmaceutical composition of the present invention contains pharmaceutical additives such as excipients, disintegrants, binders, lubricants, fluidizers, dispersants, suspending agents, emulsifiers, preservatives, and stabilizers. Things can be added as appropriate.
- the ratio of the physiologically active peptide, aminoalkyl methacrylate copolymer E, and acidic substance in the pharmaceutical composition is as follows: 1 part by weight of the biologically active peptide in an effective amount for treating or preventing a disease; Methacrylate copolymer—E is 0.1 to: L00000% by weight (preferably 0.5 to: L00000 parts by weight, more preferably 1 to L00000 parts by weight), and the acidic substance is 10% of the basic group of the polymer. It is an amount that neutralizes the above (preferably 15% or more, more preferably 30% or more, even more 40% or more, and suitably 50% or more).
- 0.1 to 100 parts by weight of L-aminoalkylmethyl acrylate copolymer E per 1 part by weight of the bioactive peptide in a pharmaceutical composition is effective for treating or preventing a disease (preferably Is from 0.5 to 100,000 parts by weight, more preferably from 1 to 100,000 parts by weight, and 0.005 to 50 parts by weight (preferably 0.01 to 30 parts by weight, more preferably 0.01 to 30 parts by weight, based on 1 part by weight of the polymer). Is 0.03 or more: L0 parts by weight).
- the pharmaceutical composition for improving oral absorption of the present invention can be applied to various preparations known per se.
- Specific preparations include, for example, ordinary preparations (tablets, capsules, solutions, powders, granules, etc.), sustained-release preparations (see, for example, International Publication Pamphlet WO94 / 06414), and colon release preparations (for example, Published pamphlet W095 / 28963), time-release or pulsed-release preparations (for example, see WO01 / 78686A1: PCT / JP01 / 03229 (filed on April 16, 2001), USSN 09 / 834,410 (filed April 2001) Month On the 12th), International Publication Pamphlet WO93 / 05771), fine particle preparations (for example, see Japanese Patent Application Laid-Open No.
- mucoadhesive preparations for example, see JP-A-5-132416
- mucoadhesive preparations for example, see JP-A-5-132416
- a mixture of the granulated product and a saccharide (eg, lactulose) that is decomposed by intestinal bacteria and generates an organic acid is coated with a polymer that is soluble in the organic acid, and then, if necessary, treated with hydroxy.
- a saccharide eg, lactulose
- the dosage of the degradation inhibitor of the present invention, the viscosity reducing agent, or the pharmaceutical composition for improving oral absorption is appropriately selected and determined according to the dosage of the physiologically active peptide used in combination. Usually, it is recommended to be about 0.001 to 100 mg per kg of body weight per adult per day, and to divide it into once or multiple times, for example, 2 to 4 times a day, depending on the use of the bioactive peptide. Can be administered.
- the degradation inhibitor of the present invention, the viscosity reducing agent, or the pharmaceutical composition for improving oral absorption is appropriately selected depending on the usage, age of the patient, gender and other conditions, the degree of the disease, etc., but usually, the bioactive peptide in the active ingredient is an effective amount capable of exerting its original action. It is good to be taken.
- the amount is appropriately determined depending on the type of the bioactive peptide to be used, and is not particularly limited. In general, it is preferably about 0.001 to 100 mg per 1 kg of body weight per adult per day.
- the formulation can be administered once a day or divided into a plurality of times, for example, 2 to 4 times.
- the pharmaceutical preparation may be, for example, a formulation of a physiologically active peptide according to a conventional method, and a coated tablet form coated with the physiologically active peptide according to a conventional method, or a solid dispersion form.
- the preparation into the solid dispersion form is carried out by a conventional method, for example, by dissolving or suspending a physiologically active peptide and an aminoalkyl methacrylate copolymer E in a suitable solvent, and then removing the solvent. Can be implemented.
- the decomposition inhibitor, the viscosity reducing agent, or the pharmaceutical composition for improving oral absorption of the present invention is prepared in a separate preparation from the bioactive peptide, it is preferably administered simultaneously with the bioactive peptide.
- FIG. 1 is a schematic diagram showing one embodiment of the pharmaceutical composition of the present invention.
- Figure (1-1) shows that aminoalkyl methacrylate copolymer E (B in the figure) and acidic substance (C in the figure) were uniformly mixed in the core containing the drug (A in the figure).
- Layer-coated dosage forms for example, granules, powders, capsules filled with them, liquids, suspensions, emulsions, and capsules filled with liquids, suspensions, emulsions, etc.
- FIG. FIG. (L-2a) and FIG. (L-2b) are schematic diagrams showing the same composition as one embodiment of the present invention.
- the composition is one embodiment of the present invention in which each component is dispersed in average as a whole.
- the dosage form in this state include powders, granules, capsules filled with granules and mixtures thereof, and tablets formed by compressing them, turnips filled with liquids, suspensions, emulsions, and the like. Cell agents and the like can be mentioned.
- Figure 2 shows a white powder obtained by dissolving 1650 g of Eudragit E100 (trade name, Rohm GmRH) and Tween80 at a ratio of 10: 1 in 2000 g of a mixture of lmol / 1 hydrochloric acid solution and ethanol (5:12) (5:12). (See Example 1, "E-SD”) is mixed with trypsin, and the structural change of trypsin before and after mixing is measured using a circular dichroism dispersometer. is there.
- Fig. 3 is a chart showing the change in the molecular weight distribution of trypsin measured by using an intermolecular interaction analysis system using ultracentrifugation for the structural change of trypsin before and after mixing trypsin and E-SD.
- FIG. S ' is the sedimentation coefficient, and the molecular weight is calculated based on the peak value.
- aminoalkyl methacrylate copolymer E used in the present invention was prepared as follows, but the aminoalkyl methacrylate copolymer E of the present invention is limited by these reference examples. Not something.
- Eudragit TMEPO (2.9 g), which is a fine powder of Eudragit TM E , was added to 50 g of purified water to prepare a test solution.
- Eudragit TM E in the test solution was completely dissolved.
- a solution obtained by dissolving 0.25 g of Tween80 in this solution was freeze-dried using an FD-81 freeze dryer (manufactured by Tokyo Rika Kikai) to obtain a white freeze-dried product. When this product lg was added to 15 g of purified water, it was completely dissolved.
- solution C A 0.5% carbopol solution was prepared (solution C).
- Solution A was mixed with solution B or solution C and shaken immediately.
- the viscosities of the solutions at 0 and 3 hours after mixing were measured with a viscometer.
- Example 1 Male Wistar X-ray rats (10 weeks old) were laparotomized under anesthesia with pentoparbital (trade name: Somnopentyl, manufactured by Schering-Brow), and the colon and anus were tied with a thread to form a large intestinal loop.
- pentoparbital trade name: Somnopentyl, manufactured by Schering-Brow
- 6 mg of Bovine insulin and 400 mg of E'SD were dissolved in 16 ml of physiological saline (2% solution of E-SD) to prepare a solution of the present invention. This solution was administered to the large intestine and small intestine loops at a dose equivalent to 100 g / kg as insulin.
- 0.25 ml of blood was collected from the jugular vein, and the plasma glucose concentration was measured.
- the plasma glucose concentration before administration was set at 100, and the plasma glucose reduction (D,% of initial *) up to 3 hours after administration was calculated. D was calculated by subtracting the area AUC (% of initial * h) under the plasma glucose concentration-time curve up to 3 hours after administration from the AUC when only physiological saline was administered.
- a solution prepared by dissolving 6 mg of bovine insulin in 20 ml of physiological saline was administered to the large intestine loop at a dose of 600 ⁇ ⁇ / kg as insulin, or 2 ml of physiological saline was administered as a control.
- the plasma glucose concentration was measured in the same manner as described above (Glucose CII Test Co., Wako Pure Chemical Industries).
- Example 2 Args-vasopressin 0.2 mg and E'SD 400 mg were dissolved in physiological saline 20 ml to prepare a solution of the present invention. This solution was administered into the large intestine and small intestine loops in an amount of 100 / kg as Arg 8 -vasopressin. At 0.5, 1, 1.5, and 2 hours after administration, 0.4 ml of blood was collected from the jugular vein, and the concentration of Arg 8 -vasopressin in plasma was measured.
- a solution prepared by dissolving 0.2 mg of Arg 8 -vasopressin in 20 ml of physiological saline was administered to the large intestine and small intestine loops at a dose of 100 g / kg equivalent as Arg 8 -vasopressin, and the same Arg 8 -vasopressin concentration was measured.
- AUC was significantly increased when both vasopressin and E_SD were administered compared to when only vasopressin was administered, and AUC was significantly increased with colon administration. Therefore, it is suggested that E-SD improves oral absorption of vasopressin.
- Example 3 1.5 g of Salmon Calcitonin (sCT) and 400 mg or 200 mg of E-SD were dissolved in 20 ml of a 1% aqueous gelatin solution to prepare a solution of the present invention. This solution was injected into the large intestine and small intestine loops at a dose of 0.6 g / kg as sCT. At 0, 1, 2, 3 and 4 hours after administration, 0.4 ml of blood was collected from the jugular vein and the calcium concentration in plasma was measured.
- sCT Salmon Calcitonin
- a solution prepared by dissolving 1.5 ⁇ m of sCT in 20 ml of 1% aqueous gelatin solution was administered to the large and small intestine loops at a dose of 0.6 g / kg as sCT, or only 1% aqueous gelatin solution was administered.
- the plasma calcium concentration was measured as described above.
- the same test as above was performed using carbopol-sodium salt 100 mg instead of E-SD.
- the substrate mass in the test solution up to 20 minutes was quantified by UV measurement (256 nm).
- the substrate decomposition rate constant K (% / min) was calculated by calculating the slope of the time-residual group mass line, assuming that the enzymatic decomposition reaction was based on a linear equation.
- Example 4 To a mixed solution of 0.3 ml of a trypsin PBS solution (0.048 mg / ml) and 1.5 ml of an E-SD aqueous solution, 0.3 ml of a PBS solution of N--benzoylarginine ethylester (1 mg / ml) was added, The base mass in the test solution after addition was measured in the same manner as above, and the K value was calculated. Three types of E-SD aqueous solutions were prepared so that the E-SD concentrations in the test solution were 5, 10, and 20 mg / ml, respectively.
- the K value decreased in a manner dependent on the amount of E-SD added, and was reduced to about half when E-SD was added at 20 mg / ml compared to when no E-SD was added.
- the results showed that the addition of E-SD reduced the enzyme activity of trypsin. Therefore, it was shown that the amino-alkyl methyl acrylate copolymer E to which the acid was added was useful as a digestive enzyme degradation inhibitor for bioactive peptide proteins.
- the state of the ⁇ -order structure of a trypsin phosphate buffer solution (0.6 mg / mL) was measured using a circular dichroism spectrometer (JASCO) at a CD spectrum of 190-250 nm. .
- trypsin phosphate buffer solution (0.6 mg / mL) and E-SD
- An equal volume of an acid buffer solution (10 mg / mL) was mixed and allowed to stand for 30 minutes, and then the CD spectrum was measured using a circular dichroism analyzer to examine the structural change of trypsin.
- the time-dependent change in the distribution of absorbance at 280 mn of a 1: 1 mixture of E_SD and E_SD solution (2.5 mg / mL) was measured every 15 minutes.
- the rotation speed was 45,000 rpm.
- the results were analyzed by the time-derivative method, and the apparent sedimentation coefficient s and its distribution g (s) were calculated.
- Example 5 elastase in PBS 0.021 mg / ml 0.1 ml and E_SD aqueous solution 1.4 ml, succinyl- (L-alanyl ) 3 -4-nitroanilide in PBS (0.2 mg / ml) 0.6 ml was added, the base mass in the test solution after the addition was measured in the same manner as above, and the K value was calculated.
- Three types of E-SD aqueous solutions were prepared so that the E-SD concentrations in the test solution were 5, 10, and 20 mg / ml, respectively.
- the K value decreased depending on the amount of E-SD added, and decreased to about half when E-SD was added at 20 mg / ml compared to when no E-SD was added.
- Insulin 500U (17.8 mg) was encapsulated in a hard gelatin capsule (# 0, CAPSUGEL M).
- the capsule was orally administered to a beagle dog (15-24 months old) together with 30 ml of water under fasting conditions.
- a dalkose measurement kit Glucose CII Test Co., Wako Pure Chemical Industries.
- the plasma glucose concentration before administration was set at 100, and the plasma glucose decrease (D,% of initial * h) and the minimum glucose concentration (Cmin,% 'of initial) after administration up to 8 hours were calculated.
- D is the one-hour plasma glucose concentration curve up to 8 hours after administration.
- Insulin 500U I7.8mg
- E'SD125mg E'SD125mg
- DL-malic acid 50mg DL-malic acid 50mg
- polyethylene glycol 6000 hereinafter PEG6000
- the tablet of the present invention was prepared by molding in 2 .
- the tablets were orally administered to beagle dogs under the same conditions as above, blood was collected, and the plasma glucose concentration was measured. D and Cmin were calculated from the obtained changes in plasma glucose concentration in the same manner as in the control example.
- Example 7 A core tablet was prepared by mixing 500 U (I7.8 mg) of insulin, 125 mg of E-SD, and 57.2 mg of DL-malic acid, and molding the mixture with an oil press at a compression pressure of 40 kg / cm 2 .
- I got Polyethylene oxide (trade name: Polyox-WSR303, manufactured by Union Power Ibid Co., Ltd .: PEO) 100 mg of PEG and 200 mg of PEG6000 are mixed to prepare a PEOZPEG mixed powder, and half of the powder is added to a tableting die. It was placed in the center of the mortar.
- the tablet of the present invention having an outer layer was prepared by molding with an oil press at a tableting pressure of 40 kg / cm 2 .
- the nucleated tablet was orally administered to a beagle dog under the same conditions as above, blood was collected, and plasma glucose concentration was measured. D and Cmin were calculated in the same manner as in Control Example 5 from the obtained changes in plasma glucose concentration.
- Example 6 With insulin alone, there was almost no decrease in blood glucose levels up to 8 hours after administration. On the other hand, in both Example 6 and Example 7, an increase in the D value and a decrease in the Cmin value were observed, and the oral administration of E-SD together with insulin showed a tendency to decrease the blood glucose level.
- the tablet that dissolves the active ingredient in the small intestine or large intestine (Example 7) is more effective than the tablet that disintegrates in the stomach (Example 6). Since the dissolution and dispersion of -SD could be suppressed, the decrease in blood glucose level tended to increase. From these results, it was shown that the effect of insulin by oral administration can be improved by using acid-added aminoalkyl methacrylate copolymer E.
- the aminoalkyl methacrylate copolymer E used as an active ingredient in the present invention is useful as an inhibitor for the degradation of bioactive peptides by digestive enzymes.
- the aminoalkyl methyl acrylate copolymer E used as an active ingredient in the present invention comprises a gastrointestinal mucosa and a mucous layer distributed on the mucosa of the gastrointestinal tract or the mucosa thereof, and a viscosity-reducing agent for the mucus layer distributed on the gastrointestinal mucosa.
- the aminoalkyl methacrylate copolymer E used as an active ingredient in the present invention has an action of improving the permeability of a bioactive peptide in a gastrointestinal mucosa and / or a mucus layer distributed on the mucous membrane. So bioactive buchi It is useful as a superior oral absorption improver for the drug.
- the pharmaceutical composition of the present invention has an effect that the amino alkyl methacrylate copolymer E suppresses the degradation of the physiologically active peptide, and reduces the viscosity of the mucus layer in the gastrointestinal mucosa and / or mucus layer distributed on the mucosa.
- the pharmaceutical composition of the present invention is useful as providing a versatile formulation technique, for example, it can be applied to several kinds of bioactive peptides such as insulin, calcitonin, and vasopressin. '
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003201886A AU2003201886A1 (en) | 2002-01-16 | 2003-01-15 | Medicinal compositions for improving oral absorption |
JP2003559549A JP5462429B2 (ja) | 2002-01-16 | 2003-01-15 | 経口吸収改善用医薬組成物 |
KR1020047009434A KR100937113B1 (ko) | 2002-01-16 | 2003-01-15 | 경구흡수 개선용 의약 조성물 |
EP03700570A EP1466626A4 (en) | 2002-01-16 | 2003-01-15 | MEDICINAL COMPOSITIONS WITH IMPROVED ORAL ABSORPTION |
CA002472449A CA2472449C (en) | 2002-01-16 | 2003-01-15 | Pharmaceutical composition for oral use with improved absorption |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34978402P | 2002-01-16 | 2002-01-16 | |
US60/349,784 | 2002-01-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003059389A1 true WO2003059389A1 (fr) | 2003-07-24 |
Family
ID=23373946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/000269 WO2003059389A1 (fr) | 2002-01-16 | 2003-01-15 | Compositions medicamenteuses presentant une meilleure absorption orale |
Country Status (8)
Country | Link |
---|---|
US (1) | US7923025B2 (ja) |
EP (1) | EP1466626A4 (ja) |
JP (2) | JP5462429B2 (ja) |
KR (1) | KR100937113B1 (ja) |
CN (1) | CN100450547C (ja) |
AU (1) | AU2003201886A1 (ja) |
CA (1) | CA2472449C (ja) |
WO (1) | WO2003059389A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008081829A1 (ja) * | 2006-12-27 | 2008-07-10 | Astellas Pharma Inc. | 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーe |
JP2013500279A (ja) * | 2009-07-30 | 2013-01-07 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | アミノ(メタ)アクリレートポリマー又はコポリマーを含有する水性炭酸媒体 |
WO2015025979A1 (ja) * | 2013-08-21 | 2015-02-26 | 株式会社Nrlファーマ | マイクロ微粒子の製造方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108295241A (zh) | 2009-06-18 | 2018-07-20 | 宁静制药公司 | 安全的去氨加压素给药 |
CA2790918C (en) | 2010-02-25 | 2019-08-06 | Evonik Roehm Gmbh | Pharmaceutical or neutraceutical formulation comprising a core and a polymeric coating |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990001329A1 (en) * | 1988-07-30 | 1990-02-22 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
JPH07138182A (ja) * | 1993-11-12 | 1995-05-30 | Toyobo Co Ltd | 口腔粘膜適用徐放性製剤 |
WO1997015297A1 (en) * | 1995-10-23 | 1997-05-01 | Theratech, Inc. | Compositions and methods for buccal delivery of pharmaceutical agents |
WO1997015296A1 (en) * | 1995-10-23 | 1997-05-01 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
JPH09278670A (ja) * | 1995-10-06 | 1997-10-28 | Fujisawa Pharmaceut Co Ltd | インシュリン様成長因子1の経口投与製剤 |
WO2000002574A1 (fr) * | 1998-07-08 | 2000-01-20 | Kirin-Amgen Inc. | Preparation en poudre pour administration par les muqueuses |
WO2000043041A1 (fr) * | 1999-01-22 | 2000-07-27 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicamenteuses presentant une meilleure absorption orale |
WO2002005786A1 (fr) * | 2000-07-17 | 2002-01-24 | Yamanouchi Pharmaceutical Co., Ltd. | Composition pharmaceutique a absorbabilite per os amelioree |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4537772A (en) | 1984-05-02 | 1985-08-27 | Merck & Co., Inc. | Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines |
US5350741A (en) | 1988-07-30 | 1994-09-27 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
US5445830A (en) | 1989-07-25 | 1995-08-29 | Otsuka Pharmaceutical Co., Ltd. | Highly absorbable pharmaceutical composition |
TW209174B (ja) * | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
ES2188657T3 (es) * | 1994-04-22 | 2003-07-01 | Yamanouchi Pharma Co Ltd | Sistema para la liberacion especifica en el colon de un farmaco. |
GB9417524D0 (en) | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
US5766820A (en) * | 1995-12-22 | 1998-06-16 | Konica Corporation | Silver halide photographic light-sensitive material and its developing methods |
US5726154A (en) * | 1996-06-28 | 1998-03-10 | University Of Utah Research Foundation | Stabilization and oral delivery of calcitonin |
DE19631085A1 (de) | 1996-08-01 | 1998-02-05 | Basf Ag | Verwendung von (Meth)acrylsäure-Maleinsäure-Copolymeren zur Verbesserung der Permeabilität der Schleimhaut |
JP2000103732A (ja) * | 1998-07-28 | 2000-04-11 | Tanabe Seiyaku Co Ltd | 腸内適所放出型製剤 |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6458383B2 (en) * | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
WO2001074397A1 (fr) * | 2000-03-31 | 2001-10-11 | Kirin Beer Kabushiki Kaisha | Preparation en poudre destinee a etre administree par les muqueuses comprenant un medicament de forme polymere et presentant une stabilite de conservation amelioree |
-
2003
- 2003-01-15 KR KR1020047009434A patent/KR100937113B1/ko not_active IP Right Cessation
- 2003-01-15 CA CA002472449A patent/CA2472449C/en not_active Expired - Fee Related
- 2003-01-15 JP JP2003559549A patent/JP5462429B2/ja not_active Expired - Fee Related
- 2003-01-15 WO PCT/JP2003/000269 patent/WO2003059389A1/ja active Application Filing
- 2003-01-15 US US10/345,051 patent/US7923025B2/en not_active Expired - Fee Related
- 2003-01-15 CN CNB038022125A patent/CN100450547C/zh not_active Expired - Fee Related
- 2003-01-15 EP EP03700570A patent/EP1466626A4/en not_active Withdrawn
- 2003-01-15 AU AU2003201886A patent/AU2003201886A1/en not_active Abandoned
-
2012
- 2012-02-01 JP JP2012019638A patent/JP2012111773A/ja not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990001329A1 (en) * | 1988-07-30 | 1990-02-22 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
JPH07138182A (ja) * | 1993-11-12 | 1995-05-30 | Toyobo Co Ltd | 口腔粘膜適用徐放性製剤 |
JPH09278670A (ja) * | 1995-10-06 | 1997-10-28 | Fujisawa Pharmaceut Co Ltd | インシュリン様成長因子1の経口投与製剤 |
WO1997015297A1 (en) * | 1995-10-23 | 1997-05-01 | Theratech, Inc. | Compositions and methods for buccal delivery of pharmaceutical agents |
WO1997015296A1 (en) * | 1995-10-23 | 1997-05-01 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
WO2000002574A1 (fr) * | 1998-07-08 | 2000-01-20 | Kirin-Amgen Inc. | Preparation en poudre pour administration par les muqueuses |
WO2000043041A1 (fr) * | 1999-01-22 | 2000-07-27 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicamenteuses presentant une meilleure absorption orale |
WO2002005786A1 (fr) * | 2000-07-17 | 2002-01-24 | Yamanouchi Pharmaceutical Co., Ltd. | Composition pharmaceutique a absorbabilite per os amelioree |
Non-Patent Citations (1)
Title |
---|
See also references of EP1466626A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008081829A1 (ja) * | 2006-12-27 | 2008-07-10 | Astellas Pharma Inc. | 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーe |
JP2013500279A (ja) * | 2009-07-30 | 2013-01-07 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | アミノ(メタ)アクリレートポリマー又はコポリマーを含有する水性炭酸媒体 |
WO2015025979A1 (ja) * | 2013-08-21 | 2015-02-26 | 株式会社Nrlファーマ | マイクロ微粒子の製造方法 |
CN105517539A (zh) * | 2013-08-21 | 2016-04-20 | Nrl制药股份有限公司 | 微粒的制造方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1798578A (zh) | 2006-07-05 |
JP2012111773A (ja) | 2012-06-14 |
CN100450547C (zh) | 2009-01-14 |
EP1466626A1 (en) | 2004-10-13 |
AU2003201886A1 (en) | 2003-07-30 |
US20030175351A1 (en) | 2003-09-18 |
KR20040077857A (ko) | 2004-09-07 |
JPWO2003059389A1 (ja) | 2005-05-19 |
US7923025B2 (en) | 2011-04-12 |
EP1466626A4 (en) | 2007-09-05 |
KR100937113B1 (ko) | 2010-01-18 |
JP5462429B2 (ja) | 2014-04-02 |
CA2472449A1 (en) | 2003-07-24 |
CA2472449C (en) | 2010-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100863146B1 (ko) | 경구 흡수 개선 의약 조성물 | |
US20210322305A1 (en) | Methods and Compositions for Oral Administration of Exenatide | |
KR100498646B1 (ko) | 경구용 펩티드 약학적 조성물 | |
US9504727B2 (en) | Oral delivery of peptide pharmaceutical compositions | |
EP3244878B1 (en) | Solid oral dosage forms | |
JP2009518437A (ja) | 速効性経口ペプチド医薬品 | |
JP2004525123A (ja) | 経口ペプチド医薬投与形および製造方法 | |
JP2012111773A (ja) | 経口吸収改善用医薬組成物 | |
WO2022049310A1 (en) | Improved pharmaceutical formulations of glp-1 receptor agonists | |
JP4599714B2 (ja) | 経口吸収改善医薬用組成物 | |
WO2022216888A1 (en) | Methods of treatment of pediatric puberty using oral formulations of leuprolide | |
WO2001064253A1 (fr) | Compositions medicinales renfermant un agent modificateur de la glycoproteine p pour administration au gros intestin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003559549 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047009434 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003700570 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 982/KOLNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2472449 Country of ref document: CA Ref document number: 20038022125 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003700570 Country of ref document: EP |